‘WORKING ON BETTER SOLUTIONS FOR ANTIMICROBIAL RESISTANCE’

“Truenat is already being viewed as a multi-disease platform and in addition to the TB programme, we expect other programmes such as the Viral Hepatitis programme, NACO and National Vector Borne Diseases Control programme to add to the wider deployment and usage of the technology at the grass root level. The Indian private sector is also able to use the Truenat platform for delivering high quality diagnostics for the full range of tests available. Truenat tests for about 30 infectious diseases are already available and another 30 plus new diseases are in development which are expected to be launched over the next 2 years. A range of open format reagents by the name Truemix are also planned again in a ready to use, room temperature stable format. We expect to establish ourselves as a major player in the global molecular diagnostics market in the coming years. At the same time, we are also working on other point of care technologies and better solutions for antimicrobial resistance (AMR) and non-infectious disease testing applications.” - SRIRAM NATARAJAN, Founder, Director & Chief Executive Officer, Molbio Diagnostics, Goa